Aspivix, a FemTech company specialising in the modernisation of gynaecological care, has announced the official launch of its breakthrough device, carevix, now available to healthcare professionals in Southern California and New York State.
The company claims the device delivers an innovative, less painful alternative to the century-old tenaculum for intrauterine device (IUD) placement and other transcervical procedures. It is the first step toward a nationwide rollout says Aspivix.
Aspivix says that carevix is the world’s first clinically proven suction-based cervical stabiliser, designed to replace the century-old tenaculum, a sharp-toothed forceps still widely used in gynaecology.
The company claims that studies demonstrate that the gentle suction technology reduces pain during IUD insertions by more than 70% and bleeding by over 80% compared to the use of a traditional tenaculum. Beyond IUDs, this new suction device is designed for a broad range of gynecological and fertility procedures, including hysteroscopies, embryo transfers, intrauterine inseminations (IUI), fallopian tube patency assessments, and endometrial biopsies.
“As we launch in Los Angeles, Orange County, and New York, we are not just introducing a new device – we are in essence redefining the standard of gynaecological care,” said Mathieu Horras, CEO of Aspivix.
“My previous IUD insertion was 10/10 painful, worse than when I broke my ankle. I’d been fearful of getting a new one. But this time was so easy. I’d always choose an IUD if it’s this easy,” said a patient from Tia Health.
This physician-first launch provides immediate access for OB-GYNs and women’s health clinics, with patient benefits following as clinics introduce the device into routine care.
“With carevix, we are giving women and people with a uterus access to a gentler, more respectful experience, because gynecological pain can be reduced, and it should never be dismissed as ‘just a pinch,’” commented Ikram Guerd, General Manager US of Aspivix.
